Jasmine Singh
Internal Medicine · Charlotte, NCNPI 1932276326
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $718 and has fallen 95.5% since, to $32 in 2023.
Across 109 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$227
- AbbVie$223
- AstraZeneca$142
- Amgen$135
- Johnson & Johnson$115
- Boehringer Ingelheim$111
- plus $749 from 19 others
What the payments were for
- Food & beverage$1,701100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $227 |
| AbbVie(2 entities) | 16 | $223 |
| AstraZeneca(2 entities) | 9 | $142 |
| Amgen(2 entities) | 10 | $135 |
| Johnson & Johnson | 7 | $115 |
| Boehringer Ingelheim | 7 | $111 |
| Esperion Therapeutics, Inc. | 5 | $92 |
| Lilly USA, LLC | 5 | $84 |
| Vifor Pharma, Inc. | 5 | $78 |
| Amarin Pharma, Inc. | 5 | $74 |
| GSK | 5 | $64 |
| Merck | 3 | $40 |
| Fresenius USA Marketing, Inc. | 2 | $35 |
| Ironwood Pharmaceuticals, Inc | 2 | $34 |
| Pfizer | 1 | $32 |
| Bayer | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Novartis | 1 | $19 |
| Calliditas Therapeutics US Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Dermira, Inc. | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
How this compares
$1,701 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Losartan Potassium | 15 | $336 |
| Atorvastatin Calcium | 22 | $266 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Charlotte
- Saad UsmaniCharlotte$551K
- Marc JohnsonCharlotte$342K
- Maithili ChitnavisCharlotte$267K
- Jonathan SchwartzCharlotte$193K
- Perry RoyCharlotte$135K
- Benjamin BrooksCharlotte$91K
- Mark SchwartzCharlotte$80K
- Thomas WalshCharlotte$64K
- Lisa BellanfonteCharlotte$45K
- Nirmish ShahDurham$862K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.